News
3 Beaten-Up Biotech Stocks: Are They Bargains?
The iShares Nasdaq Biotechnology Index has tacked on a healthy gain of around 15% so far this year, without any help from Celldex Therapeutics, Inc. (NASDAQ: CLDX), Agenus Inc. (NASDAQ: AGEN), or
This Struggling Marijuana Stock Finally Launched Its Highly Anticipated Drug
If you look around, chances are you won't find many marijuana stocks struggling. In fact, over the trailing one-year period, 12 out of 13 pot stocks with a market cap above $200 million had risen
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
How many big biotech acquisitions can you name that have occurred so far in 2017?Johnson & Johnson (NYSE: JNJ) spent $30 billion to buy Swiss biotech Actelion. That's one. Then there's... well
This Technology Could Make You Rich -- and Change the World As We Know It
Revolutionary, game-changing, groundbreaking.These words are probably used too often in describing new innovations. The reality is that most new products and technologies don't live up to the hype
3 Marijuana Stocks That Could Make You the Most Money in the 2nd Half of 2017
For investors who enjoyed the huge run of marijuana stocks last year, the first half of 2017 probably hasn't been as exciting. Several of the largest marijuana stocks haven't performed all that great
Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs
Ionis Pharmaceuticals (NASDAQ: IONS) reported second-quarter earnings earlier this week and then followed up on Friday with a disclosure that it's getting full rights back to two of its drugs
Intrexon Depended on 1 Customer for 58% of First-Half 2017 Revenue Growth
The single biggest problem facing engineered biology conglomerate Intrexon (NYSE: XON) heading into the second quarter of 2017 was its dependency on small- and micro-cap companies for a significant
2 Marijuana Stocks That Turned $10,000 Into $125,000 and $300,000, Respectively
When it comes to top-performing industries, you'd have a tough time surpassing the returns of marijuana stocks. Of the 13 marijuana stocks with a market cap in excess of $200 million, over half have
Better Buy: Exact Sciences Corporation vs. Opko Health
"It was the best of times, it was the worst of times..."Charles Dickens wasn't referring to Exact Sciences (NASDAQ: EXAS) and Opko Health (NASDAQ: OPK) when he wrote those words, but they're certainly
Why Impax Laboratories Inc Is Up for a Second Straight Day
Impax Laboratories (NASDAQ: IPXL) closed up 10% on Thursday after jumping 9.6% yesterday following its second-quarter earnings report. Today's move seems to be a continuation of yesterday's jump
Why Pan American Silver, Chefs' Warehouse, and Perrigo Jumped Today
Thursday was one of the worst sessions that the stock market has seen in several months, with major benchmarks falling 1% or more. Investors are growing increasingly nervous about the rising tensions
Here's Why Perrigo Company Rose as Much as 20.5% Today
Shares of Perrigo Company (NYSE: PRGO) rose over 20% this morning after the healthcare leader released second-quarter 2017 financial results and adjusted full-year 2017 guidance. While revenue slipped
3 High-Yield Healthcare Stocks
The healthcare sector is a natural hunting ground for income investors, since consumers demand access to high-quality healthcare products in good times and bad. That fact helps keep many healthcare
5 Reasons Valeant's Situation Could Get Worse
Valeant Pharmaceuticals (NYSE: VRX) announced some good news in its second-quarter update on Tuesday. The drugmaker now expects to cut its debt by $5 billion sooner than its previous target of
Organovo Holdings Revenue Is Growing at a Snail's Pace Compared With Prior Quarters
It's been a crazy year for Organovo Holdings (NASDAQ: ONVO) so far. The 3D bioprinting company's former CEO abruptly left in April. Organovo disappointed investors with its fourth-quarter and
Earnings Hangover Sacks Valeant Pharmaceuticals' Stock, Sending Shares Down 10%
Shares of embattled drugmaker Valeant Pharmaceuticals (NYSE: VRX) are pulling an about-face after initially moving higher following the release of its second-quarter earnings results before the
Why Red Robin Gourmet Burgers, Hertz Global Holdings, and Novo Nordisk Jumped Today
The stock market fell again on Wednesday, posting what has become an increasingly rare two-day losing streak. Major benchmarks gave up modest amounts of ground in the wake of some disappointing
Here's Why Progenics Pharmaceuticals, Inc. Lost Ground Today
Despite upbeat recent developments, shares of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) fell 15.3% during Wednesday's session. The biotech reported solid progress with clinical-stage candidates
The Sole Reason Amicus Therapeutics, Inc. Exploded 29% Higher in July
Shares of Amicus Therapeutics (NASDAQ: FOLD), a biopharmaceutical company focused on the development rare-disease drugs, exploded higher by 29% during the month of July, according to data from S&P
The 1 Very Clear Reason Arena Pharmaceuticals, Inc. Skyrocketed 41% in July
Shares of Arena Pharmaceuticals (NASDAQ: ARNA), a biopharmaceutical company focused on the development of small-molecule drugs for the treatment of a variety of diseases, catapulted 41% during July
Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today
In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous
2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July
Shares of Achillion Pharmaceuticals (NASDAQ: ACHN), a clinical-stage drug developer focused on small-molecule treatments for infectious diseases, such as hepatitis C, turned in a dismal July and sank
Why Achillion Pharmaceuticals Is Shooting 25% Higher Today
After the company updated investors on its second-quarter financials and the progress it's making in its clinical-stage drug pipeline, shares in Achillion Pharmaceuticals (NASDAQ: ACHN) are soaring
Why Impax Laboratories Inc Jumped Higher Today
Impax Laboratories (NASDAQ: IPXL) is up 7.6% at 11:53 a.m. EDT, having been up as much as 17.9% earlier today, after reporting solid second-quarter earnings.Revenue from the drugmaker was up 17% year
Here's Why NantKwest Inc. Tumbled 21.1% in July
Shares of NantKwest (NASDAQ: NK), a clinical-stage biotech company primarily focused on immunotherapy compounds that treat cancer, fell by 21% in July, according to S&P Global Market Intelligence. The